Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results

New Eptinezumab Phase III Trial Results



Recent findings from the phase III SUNRISE trial highlight the significant impact of Eptinezumab (Vyepti®) in treating chronic migraines within the Asian population. Presented during the European Academy of Neurology's 2025 Annual Congress, the data offers crucial insights into the effectiveness of Eptinezumab compared to placebo in reducing migraine occurrences.

Key Findings of the SUNRISE Trial


The trial demonstrated that participants receiving Eptinezumab saw impressive reductions in their mean monthly migraine days (MMDs), with those on the 300 mg dose recording a decrease of 7.5 days and those on the 100 mg dose showing a decrease of 7.2 days during the initial 12 weeks. In stark contrast, the placebo group experienced only a 4.8-day reduction.

Additionally, patients taking Eptinezumab were four times more likely to achieve a notable reduction of 75% or more in their migraine days within the first four weeks. This dramatic effect reaffirms the potential of Eptinezumab as a leading preventative treatment option.

Immediate Efficacy and Long-Term Benefits


The trial's design enabled researchers to evaluate not just the total effectiveness of Eptinezumab, but also the speed at which it alleviated symptoms. Notably, many participants reported being free from migraines just one day after their first treatment, emphasizing the rapid onset of relief EFptinezumab provides. Efficacy was consistent across several metrics, confirming improvements in the frequency and severity of migraine attacks compared to those receiving placebo.

Addressing Unmet Medical Needs


eptinezumab’s introduction is particularly vital for the Asian market, where access to effective migraine treatment has historically been hindered. As Johan Luthman, Lundbeck’s EVP and Head of R&D noted, the trial results are aligned with earlier studies conducted in diverse populations. This consistency will play a pivotal role in enhancing access to migraine treatments in Asia, where many patients remain under-treated.

Safety Profile of Eptinezumab


Throughout the trial, Eptinezumab displayed a safety profile comparable to placebo. Most common adverse events were mild, including cases of nasopharyngitis and COVID-19. These findings add another layer of assurance for both physicians and patients regarding the introduction of Eptinezumab as a mainstream preventive measure against chronic migraines.

Future Steps Post-Trial


Following these promising results from the SUNRISE trial, discussions with regulatory authorities are underway aiming to facilitate the availability of Eptinezumab for migraine patients across Asia. As the need for effective preventive treatments grows, Lundbeck is prepared to meet this demand while also contributing to the global understanding and management of migraine disorders.

Understanding Migraine Disorders


Migraines are not just mere headaches; they're debilitating neurological conditions that significantly affect millions of individuals globally. Characterized by severe pain often accompanied by symptoms like nausea and sensitivity to light, migraines can substantially impede daily functioning and quality of life. With approximately 14.3% of adults in China currently living with migraine, the need for effective management strategies in Asia is more critical than ever.

Conclusion


The breakthrough results of the SUNRISE trial for Eptinezumab are a promising development within the field of migraine treatment, particularly for Asian populations. Not only do they demonstrate significant clinical improvements, but they also pave the way for broader acceptance and usage of effective migraine prevention strategies across a region that grapples with a high prevalence of this disorder. As Lundbeck moves towards making this treatment accessible, hope mounts for the many suffering from chronic migraines who seek reliable and effective medical solutions.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.